Our team produces media releases, reports, policy papers and other informative content to keep you up to date on the most pressing issues facing our industry. Here in our resources section, you’ll find our most recent work.
ANALYSIS & REPORTS
Many products coming to market are poorly served by traditional negotiation approaches. This document describes innovative agreements being used in jurisdictions outside Canada. We prepared it to guide discussions with the pCPA Governing Council on the merits of jointly developing an innovative agreements framework.
Our Code of Ethical Practices guides the activities of all our members’ employees as they interact with stakeholders to commercialize prescription medicines (excluding medical devices and over-the-counter products). Adherence to the Code is a condition of membership.
INFOGRAPHICS & DATA
The process for Canadians to access new medicines is extremely complex and involves several different federal, provincial, and territorial agencies. It takes two years following approval (732 days) for Canadian patients to get access to a drug in the public plan, whereas those in the private plan get access to a drug in less than one year (226 days).
Canadians relying on public insurance plans face significant delays accessing new medicines. This graph breaks down the sequential approval and listing process, and demonstrates how long it takes Canadians to access innovative medicines.